Skip to main content
Equibles
KURA logo

KURA · Kura Oncology, Inc. · Webcasts, Transcripts & Audio

Track KURA — free

Use KURA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KURA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$10.65 +0.13 (+1.24%)
Russell 2000 member Rebalance outlook locked
Market Cap
$935.87M
Shares
88.96M
Volume · Oct 8 1.64M Avg daily vol (3M) 1.77M

Kura Oncology, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Kura Oncology, Inc. (KURA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $14.11M −$57.43M '25 Q1 25-05-01 · $15.29M −$66.12M '25 Q2 25-08-07 · $20.75M −$74.12M '25 Q3 25-11-04 · $17.34M −$81.00M '25 Q4 26-03-05 ▲29.5% $18.27M −$73.33M '26 Q1 26-05-12 LATEST ▲36.5% $20.87M −$68.33M '26 Q2 26-08-12
Earnings call
FY26 · Q2
2026-08-12
Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call
Revenue
$20.87M
▲ 36.5% YoY
Diluted EPS
$-0.77
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call
Revenue
$18.27M
▲ 29.5% YoY
Diluted EPS
$-0.83
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
Kura Oncology, Inc. (KURA) Q4 2025 Earnings Call Transcript
Confident tone Comzifty commercial launch Combination strategy in AML Frontline AML development (COMET-017)
Revenue
$17.34M*
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Kura Oncology, Inc. (KURA) Q3 2025 Earnings Call Transcript
Confident tone Ziftomenib regulatory progress (FDA/PDUFA) Differentiation vs. competitors (menin inhibitors) ASH data presentations and analyst event
Revenue
$20.75M
Diluted EPS
$-0.85
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Kura Oncology, Inc. (KURA) Q2 2025 Earnings Call Transcript
Confident tone Ziftomenib AML Development (KOMET program) Frontline AML Expansion (Phase III) FTI Pipeline (KO-2806) and ESMO
Revenue
$15.29M
Diluted EPS
$-0.75
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript
Confident tone Ziftomenib NDA submission and regulatory progress Frontline AML combination program (KOMET-007/008/017) GIST / solid tumor expansion
Revenue
$14.11M
Diluted EPS
$-0.66
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Kura Oncology, Inc. (KURA) Q4 2024 Earnings Call Transcript
Confident tone Ziftomenib NDA submission and regulatory milestones Frontline AML development (KOMET-017) GIST expansion (KOMET-015)
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript
Confident tone Ziftomenib menin inhibitor program KOMET-007 combination trial in AML GIST solid tumor opportunity
Diluted EPS
$-0.63
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Kura Oncology, Inc. (KURA) Q2 2024 Earnings Call Transcript
Confident tone Ziftomenib monotherapy in NPM1-mutant AML (KOMET-001) GIST / solid tumor expansion Frontline combination strategies (KOMET-007)
Diluted EPS
$-0.59
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript
Confident tone Ziftomenib Breakthrough Therapy Designation and AML pipeline Ziftomenib combination trials (KOMET-007) Menin inhibitor pipeline expansion beyond leukemia
Diluted EPS
$-0.59
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-30
Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript
Confident tone Ziftomenib clinical data (KOMET-007) KO-2806 farnesyl transferase inhibitor (FIT-001) Ziftomenib regulatory / pivotal planning
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Kura Oncology, Inc. (KURA) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.50
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Kura Oncology, Inc. (KURA) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.53
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Kura Oncology, Inc. (KURA) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.50
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Kura Oncology, Inc. (KURA) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Kura Oncology, Inc. (KURA) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.53
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Kura Oncology, Inc. (KURA) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.52
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Kura Oncology, Inc. (KURA) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.49
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Kura Oncology, Inc. (KURA) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Kura Oncology, Inc. (KURA) Q3 2021 Earnings Call Transcript
Diluted EPS
$-0.50
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Kura Oncology, Inc. (KURA) Q2 2021 Earnings Call Transcript
Diluted EPS
$-0.51
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Kura Oncology, Inc. (KURA) Q1 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
Kura Oncology, Inc. (KURA) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Kura Oncology, Inc. (KURA) Q3 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Kura Oncology, Inc. (KURA) Q2 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-04
Kura Oncology, Inc. (KURA) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
Kura Oncology, Inc. (KURA) Q4 2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 webcasts
Key facts CIK 1422143 CUSIP 50127T109 13F (30d) 9 filings 9 filers Visit website Investor relations